Critical Limb Ischemia (CLI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Critical Limb Ischemia (CLI) Market Outlook

Thelansis’s “Critical Limb Ischemia (CLI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Critical Limb Ischemia (CLI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Critical Limb Ischemia (CLI) Overview

Critical limb ischemia (CLI) represents the most severe manifestation of peripheral artery disease, characterized by chronic ischemic rest pain, ulceration, or gangrene due to peripheral arterial vessel occlusion. Diagnosis of CLI relies on clinical assessments, including the ankle-brachial index (ABI), toe systolic pressure, and transcutaneous oxygen pressure (TcPO2). CLI diagnosis is confirmed when ischemic rest pain coexists with an ankle pressure <50 mmHg or a toe pressure <30 mmHg, or in patients with foot ulcers or gangrene exhibiting an ankle pressure <70 mmHg, a toe systolic pressure <50 mmHg, or TcPO2 <30 mmHg. CLI typically arises from multi-segmental peripheral artery disease, resulting in compromised blood flow to peripheral tissues. Concurrent impairment in cardiac output can exacerbate peripheral perfusion in CLI patients. Diminished tissue oxygenation and nutrition may lead to claudication or rest pain, although these symptoms may be attenuated or absent in diabetic patients with neuropathy.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources &amp; assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Critical Limb Ischemia (CLI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034